Tech Company M&A Transactions
Semnur Pharmaceuticals Acquisition
Semnur Pharmaceuticals, based in Los Altos, was bought by Scintilla Pharmaceuticals. The companies indicated that total deal value was $200 million.
Transaction Overview
Company Name
Acquired By
Announced On
8/18/2016
Transaction Type
M&A
Amount
$200,000,000
M&A Terms
In consideration for the acquisition, Scintilla will pay Semnur's equity holders an initial payment of $60 million, consisting of $40 million in cash and $20 million in shares of common stock of Sorrento. In addition, additional cash consideration of up to $140 million may be paid by Scintilla to Semnur's equity holders upon achievement of certain development, product approval and commercial milestones. Following the closing of the announced acquisitions Scintilla will operate as a stand-alone company focused on pain management.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
4970 El Camino Real 205
Los Altos, CA 94022
USA
Los Altos, CA 94022
USA
Phone
Website
Email Address
Not Recorded
Overview
Semnur Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the clinical and commercial development of innovative products that meet the needs of pain management practitioners and their patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jaisim Shah
Co-Founder
Mahendra Shah
Browse more venture capital transactions:
Prev: 8/17/2016: Rubrik venture capital transaction
Next: 8/19/2016: Progenity venture capital transaction
Share this article
News on VC Transactions
We report on all VC transactions involving tech companies. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs